title: Early versus late coronary stenting following acute myocardial infarction: results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction).
abstract: This study was undertaken to determine the feasibility and safety of coronary stenting in acute myocardial infarction (AMI). In AMI, primary percutaneous transluminal coronary angioplasty (PTCA) is accepted as the preferred method of reperfusion for patients presenting at highly experienced centres. Until recently, however, stenting has been avoided during AMI because of a potential high risk of thrombosis. This prospective observational study carried out in 20 centres and included 648 consecutive patients who underwent PTCA with stent implantation for AMI. Of these 648 patients, 269 (41.5%, Group 1) were dilated early (< 24 hr) after the onset of the symptoms (75% treated by direct PTCA) and 379 (58.5%, Group 2) were dilated between 24 hr and 14 days after AMI. Combined therapy with ticlopidin and aspirin was used after the procedure. Bailout stenting occurred more often in Group 1 than in Group 2 (17% vs. 9.5%)(P < 0.05). Angiographic successful stenting was similar in both groups of patients (96% vs. 97%). During the hospital follow-up period, stent thrombosis occurred in eight patients (3%) in Group 1 and in six patients (1.6%) in Group 2 (NS). There was 14 deaths (5.2%) in Group 1 and 11 deaths (3.9%) in Group 2 (NS). After multivariate analysis bailout stenting was identified as the sole predictor of stent thrombosis (P < 0.0001). Vascular access-site complications occurred in six patients (1%) with no difference between the two groups. This study indicates that patients who receive a coronary stent in AMI can be managed safely with antiplatelet therapy. Randomized studies are needed to determine the precise indication for coronary stenting as an adjunct to primary PTCA.
authors.affiliation: Unité de Pathologie Coronaire et de Cardiologie Interventionnelle, Hôpital Emile Muller, Mulhouse, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Monassier
authors.forename: M
authors.initials: M
authors.lastname: Hamon
authors.forename: J
authors.initials: J
authors.lastname: Elias
authors.forename: L
authors.initials: L
authors.lastname: Maillard
authors.forename: C
authors.initials: C
authors.lastname: Spaulding
authors.forename: P
authors.initials: P
authors.lastname: Raynaud
authors.forename: A
authors.initials: A
authors.lastname: Cribier
authors.forename: P
authors.initials: P
authors.lastname: Barragan
authors.forename: J M
authors.initials: JM
authors.lastname: Juliard
authors.forename: T
authors.initials: T
authors.lastname: Lefevre
authors.forename: P
authors.initials: P
authors.lastname: Aubry
authors.forename: J P
authors.initials: JP
authors.lastname: Faugier
authors.forename: C
authors.initials: C
authors.lastname: Masquet
authors.forename: P
authors.initials: P
authors.lastname: Rioux
authors.forename: M
authors.initials: M
authors.lastname: Bedossa
authors.forename: P
authors.initials: P
authors.lastname: Joly
authors.forename: P Y
authors.initials: PY
authors.lastname: Petiteau
authors.forename: T
authors.initials: T
authors.lastname: Royer
authors.forename: M C
authors.initials: MC
authors.lastname: Morice
authors.forename: R
authors.initials: R
authors.lastname: Roriz
authors.forename: S
authors.initials: S
authors.lastname: Cattan
authors.forename: P
authors.initials: P
authors.lastname: Meyer
authors.forename: D
authors.initials: D
authors.lastname: Blanchard
authors.forename: K
authors.initials: K
authors.lastname: Khalifé
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D001241:Aspirin / Q000627:therapeutic use; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D012042:Registries; D015607:Stents; D013927:Thrombosis / Q000517:prevention & control; D013988:Ticlopidine / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin